These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35885056)

  • 1. The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure.
    Berezin AA; Fushtey IM; Berezin AE
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients.
    Berezin AA; Fushtey IM; Berezin AE
    J Cardiovasc Dev Dis; 2022 Jan; 9(1):. PubMed ID: 35050233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
    Berezin AA; Obradovic Z; Fushtey IM; Berezina TA; Novikov EV; Schmidbauer L; Lichtenauer M; Berezin AE
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure.
    Berezina TA; Fushtey IM; Berezin AA; Pavlov SV; Berezin AE
    Adv Ther; 2024 Jan; 41(1):292-314. PubMed ID: 37935870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
    Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
    JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association of plasma amino-terminal pro-A-, B- and C-type natriuretic peptide levels with NYHA grade and echocardiographic derived parameters of cardiac function in heart failure patients].
    Zhao XY; Yang YJ; Zhang J; Kang LM; Wei BQ; Gao XJ; Lü R; Zhang CL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):486-90. PubMed ID: 19927626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 11. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.
    Zelniker TA; Morrow DA; Mosenzon O; Goodrich EL; Jarolim P; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding J; Bode C; Lewis BS; Gause-Nilsson I; Langkilde AM; Fredriksson M; Raz I; Sabatine MS; Wiviott SD
    Eur J Heart Fail; 2021 Jun; 23(6):1026-1036. PubMed ID: 33269486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure.
    Kurdi H; Shah P; Barker S; Harris D; Dicken B; Edwards C; Jenkins G
    Br J Cardiol; 2021; 28(2):18. PubMed ID: 35747454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure.
    Rusconi PG; Ludwig DA; Ratnasamy C; Mas R; Harmon WG; Colan SD; Lipshultz SE
    Am Heart J; 2010 Oct; 160(4):776-83. PubMed ID: 20934575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
    Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
    Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.